Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Science and art of protein formulation development.

Wang W, Ohtake S.

Int J Pharm. 2019 Sep 10;568:118505. doi: 10.1016/j.ijpharm.2019.118505. Epub 2019 Jul 12. Review.

PMID:
31306712
2.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.

Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T.

Blood Adv. 2019 Feb 12;3(3):312-319. doi: 10.1182/bloodadvances.2018025981.

3.

Bulk Dynamic Spray Freeze-Drying Part 2: Model-Based Parametric Study for Spray-Freezing Process Characterization.

Sebastião IB, Bhatnagar B, Tchessalov S, Ohtake S, Plitzko M, Luy B, Alexeenko A.

J Pharm Sci. 2019 Jun;108(6):2075-2085. doi: 10.1016/j.xphs.2019.01.011. Epub 2019 Jan 23.

PMID:
30682340
4.

Bulk Dynamic Spray Freeze-Drying Part 1: Modeling of Droplet Cooling and Phase Change.

Sebastião IB, Bhatnagar B, Tchessalov S, Ohtake S, Plitzko M, Luy B, Alexeenko A.

J Pharm Sci. 2019 Jun;108(6):2063-2074. doi: 10.1016/j.xphs.2019.01.009. Epub 2019 Jan 21.

PMID:
30677417
5.

Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.

Yarbrough M, Hodge T, Menard D, Jerome R, Ryczek J, Moore D, Baldus P, Warne N, Ohtake S.

J Pharm Sci. 2019 Apr;108(4):1631-1635. doi: 10.1016/j.xphs.2018.11.031. Epub 2018 Nov 29.

PMID:
30502482
6.

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.

Kawahara T, Ishiguro Y, Ohtake S, Kato I, Ito Y, Ito H, Makiyama K, Kondo K, Miyoshi Y, Yumura Y, Hayashi N, Hasumi H, Osaka K, Muraoka K, Izumi K, Teranishi JI, Uemura H, Yao M, Nakaigawa N.

BMC Urol. 2018 Nov 6;18(1):97. doi: 10.1186/s12894-018-0414-8.

7.

Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.

Miyoshi Y, Ohtaka M, Kawahara T, Ohtake S, Yasui M, Uemura K, Yoneyama S, Yokomizo Y, Uemura H, Miyamoto H, Yao M.

Urol Int. 2019;102(1):37-42. doi: 10.1159/000493324. Epub 2018 Oct 16.

PMID:
30326476
8.

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.

Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).

Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24.

PMID:
30251205
9.

Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.

Ohtake S, Kawahara T, Ishiguro Y, Takeshima T, Kuroda S, Izumi K, Miyamoto H, Uemura H.

Mol Clin Oncol. 2018 Sep;9(3):302-304. doi: 10.3892/mco.2018.1665. Epub 2018 Jul 3.

10.

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.

Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.

Leukemia. 2019 Feb;33(2):358-370. doi: 10.1038/s41375-018-0233-7. Epub 2018 Aug 9.

PMID:
30093681
11.

Freezing of Aqueous Solutions and Chemical Stability of Amorphous Pharmaceuticals: Water Clusters Hypothesis.

Shalaev E, Soper A, Zeitler JA, Ohtake S, Roberts CJ, Pikal MJ, Wu K, Boldyreva E.

J Pharm Sci. 2019 Jan;108(1):36-49. doi: 10.1016/j.xphs.2018.07.018. Epub 2018 Jul 25.

12.

Renal Cell Carcinoma in a Horseshoe Kidney Treated with Laparoscopic Partial Nephrectomy.

Ohtake S, Kawahara T, Noguchi G, Nakaigawa N, Chiba K, Uemura H, Yao M, Makiyama K.

Case Rep Oncol Med. 2018 Jun 7;2018:7135180. doi: 10.1155/2018/7135180. eCollection 2018.

13.

Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.

Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group.

Support Care Cancer. 2018 Dec;26(12):4187-4198. doi: 10.1007/s00520-018-4292-0. Epub 2018 Jun 2.

PMID:
29860713
14.

Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.

Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T.

Ann Hematol. 2018 Sep;97(9):1535-1545. doi: 10.1007/s00277-018-3323-8. Epub 2018 Apr 24.

15.

Fluorescent Light-Guided Cystoscopy with 5-ALA Aids in Accurate Surgical Margin Detection for TURBO: A Case Report.

Takamoto D, Kawahara T, Ohtake S, Mochizuki T, Kuroda S, Nakaigawa N, Izumi K, Miyoshi Y, Makiyama K, Yao M, Sawazumi T, Inayama Y, Ohta J, Uemura H.

Case Rep Oncol. 2018 Mar 15;11(1):164-167. doi: 10.1159/000487390. eCollection 2018 Jan-Apr.

16.

Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.

Noguchi G, Tsutsumi S, Yasui M, Ohtake S, Umemoto S, Nakaigawa N, Yao M, Kishida T.

BMC Urol. 2018 Apr 18;18(1):26. doi: 10.1186/s12894-018-0339-2.

17.

One percent chlorhexidine-alcohol for preventing central venous catheter-related infection during intensive chemotherapy for patients with haematologic malignancies.

Ohtake S, Takahashi H, Nakagawa M, Uchino Y, Miura K, Iriyama N, Nakayama T, Hatta Y, Takei M.

J Infect Chemother. 2018 Jul;24(7):544-548. doi: 10.1016/j.jiac.2018.03.001. Epub 2018 Apr 4.

PMID:
29627326
18.

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.

Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K.

Ann Hematol. 2018 Aug;97(8):1481-1483. doi: 10.1007/s00277-018-3281-1. Epub 2018 Mar 1. No abstract available.

PMID:
29497807
19.

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.

Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG.

Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17.

PMID:
29360622
20.

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.

Kamijo R, Itonaga H, Kihara R, Nagata Y, Hata T, Asou N, Ohtake S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T, Kiyoi H, Miyazaki Y.

Leuk Res. 2018 Feb;65:34-41. doi: 10.1016/j.leukres.2017.12.006. Epub 2018 Jan 2.

PMID:
29306105
21.

Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K.

Ann Hematol. 2018 Jan;97(1):73-81. doi: 10.1007/s00277-017-3156-x. Epub 2017 Dec 2.

PMID:
29196987
22.

Health science students' attitudes towards healthcare teams: A comparison between two universities.

Makino T, Lee B, Matsui H, Tokita Y, Shinozaki H, Kanaizumi S, Abe Y, Saitoh T, Tozato F, Igarashi A, Sato M, Ohtake S, Tabuchi N, Inagaki M, Kama A, Watanabe H.

J Interprof Care. 2018 Mar;32(2):196-202. doi: 10.1080/13561820.2017.1372396. Epub 2017 Nov 21.

PMID:
29161164
23.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H.

Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12.

PMID:
29027108
24.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
25.

Effect of Water on the Chemical Stability of Amorphous Pharmaceuticals: 2. Deamidation of Peptides and Proteins.

Ohtake S, Feng S, Shalaev E.

J Pharm Sci. 2018 Jan;107(1):42-56. doi: 10.1016/j.xphs.2017.09.003. Epub 2017 Sep 15.

PMID:
28923320
26.

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T.

Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15.

PMID:
28914260
27.

Fracture Risk in Prostate Cancer during Hormonal Therapy.

Kawahara T, Fusayasu S, Ohtake S, Ito H, Miyoshi Y, Yao M, Uemura H.

Curr Urol. 2017 Jul;10(2):111-112. doi: 10.1159/000447162. Epub 2017 May 30. No abstract available.

28.

Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer.

Ohtaka M, Miyoshi Y, Kawahara T, Ohtake S, Yasui M, Uemura K, Yoneyama S, Hattori Y, Teranishi JI, Yokomizo Y, Uemura H, Miyamoto H, Yao M.

Urol Oncol. 2017 Oct;35(10):607.e9-607.e14. doi: 10.1016/j.urolonc.2017.05.019. Epub 2017 Jun 20.

PMID:
28641939
29.

Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Iriyama N, Miura K, Hatta Y, Kobayashi S, Uchino Y, Kurita D, Sakagami H, Takahashi H, Sakagami M, Kobayashi Y, Nakagawa M, Ohtake S, Iizuka Y, Takei M.

Oncol Lett. 2017 May;13(5):3803-3808. doi: 10.3892/ol.2017.5920. Epub 2017 Mar 27.

30.

A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.

Kasahara R, Kawahara T, Ohtake S, Saitoh Y, Tsutsumi S, Teranishi JI, Miyoshi Y, Nakaigawa N, Yao M, Kobayashi K, Uemura H.

Biomed Res Int. 2017;2017:7981549. doi: 10.1155/2017/7981549. Epub 2017 Apr 13.

31.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

32.

Minimally invasive surgery for esophageal cancer after esophageal perforation.

Murakawa K, Ono K, Yamamura Y, Niwa H, Yamamoto H, Muto J, Kato K, Ichinokawa M, Yoshioka T, Ohtake S.

Asian J Endosc Surg. 2017 Nov;10(4):407-410. doi: 10.1111/ases.12379. Epub 2017 Mar 28.

PMID:
28349648
33.

Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, Kakihana K, Dobashi N, Sugiura I, Onishi Y, Maeda T, Imai K, Ohtake S, Miyazaki Y, Ohnishi K, Matsuo K, Naoe T.

Am J Hematol. 2017 Apr;92(4):367-374. doi: 10.1002/ajh.24653. Epub 2017 Feb 21.

34.

Gene analysis of six cases of congenital protein S deficiency and functional analysis of protein S mutations (A139V, C449F, R451Q, C475F, A525V and D599TfsTer13).

Taniguchi F, Morishita E, Sekiya A, Nomoto H, Katsu S, Kaneko S, Asakura H, Ohtake S.

Thromb Res. 2017 Mar;151:8-16. doi: 10.1016/j.thromres.2016.12.018. Epub 2016 Dec 24.

PMID:
28088608
35.

Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 Nov 29;48(12):1591. doi: 10.1038/ng1216-1587a. No abstract available.

PMID:
27898077
36.

Causative genetic mutations for antithrombin deficiency and their clinical background among Japanese patients.

Sekiya A, Taniguchi F, Yamaguchi D, Kamijima S, Kaneko S, Katsu S, Hanamura M, Takata M, Nakano H, Asakura H, Ohtake S, Morishita E.

Int J Hematol. 2017 Mar;105(3):287-294. doi: 10.1007/s12185-016-2142-8. Epub 2016 Nov 17.

PMID:
27858332
37.

Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.

Ohtake S, Kawahara T, Kasahara R, Ito H, Osaka K, Hattori Y, Teranishi JI, Makiyama K, Mizuno N, Umemoto S, Miyoshi Y, Nakaigawa N, Miyamoto H, Yao M, Uemura H.

Biomed Res Int. 2016;2016:9846823. Epub 2016 Sep 8.

38.

A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.

Kurita D, Takeuchi K, Kobayashi S, Hojo A, Uchino Y, Sakagami M, Ohtake S, Takahashi H, Miura K, Iriyama N, Sugitani M, Miyoshi H, Hatta Y, Ohshima K, Takei M.

Virchows Arch. 2016 Oct;469(4):471-6. doi: 10.1007/s00428-016-1995-9. Epub 2016 Jul 25.

PMID:
27457074
39.

ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion.

Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, Netto GJ, Ishiguro H, Miyamoto H.

Oncotarget. 2016 Aug 16;7(33):53599-53610. doi: 10.18632/oncotarget.10679.

40.

Plasma cell maturity as a predictor of prognosis in multiple myeloma.

Iriyama N, Miura K, Hatta Y, Uchino Y, Kurita D, Takahashi H, Sakagami H, Sakagami M, Kobayashi Y, Nakagawa M, Ohtake S, Iizuka Y, Takei M.

Med Oncol. 2016 Aug;33(8):87. doi: 10.1007/s12032-016-0803-3. Epub 2016 Jul 6.

PMID:
27383407
41.

Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.

Takahashi H, Miura K, Nakagawa M, Sugitani M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, Iriyama N, Kobayashi S, Hojo A, Kobayashi Y, Hirabayashi Y, Kusuda M, Hatta Y, Nakayama T, Takei M.

Leuk Lymphoma. 2016 Dec;57(12):2784-2790. Epub 2016 Apr 13.

PMID:
27071312
42.

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 May;48(5):569-74. doi: 10.1038/ng.3535. Epub 2016 Mar 28. Erratum in: Nat Genet. 2016 Nov 29;48(12 ):1591.

PMID:
27019113
43.

Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.

Kawahara T, Furuya K, Nakamura M, Sakamaki K, Osaka K, Ito H, Ito Y, Izumi K, Ohtake S, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Miyamoto H, Yao M, Uemura H.

BMC Cancer. 2016 Mar 5;16:185. doi: 10.1186/s12885-016-2219-z.

44.

Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.

Lovalenti PM, Anderl J, Yee L, Nguyen V, Ghavami B, Ohtake S, Saxena A, Voss T, Truong-Le V.

Pharm Res. 2016 May;33(5):1144-60. doi: 10.1007/s11095-016-1860-1. Epub 2016 Jan 27.

PMID:
26818839
45.

Thrombosis Prediction Based on Reference Ranges of Coagulation-Related Markers in Different Stages of Pregnancy.

Sekiya A, Hayashi T, Kadohira Y, Shibayama M, Tsuda T, Jin X, Nomoto H, Asakura H, Wada T, Ohtake S, Morishita E.

Clin Appl Thromb Hemost. 2017 Oct;23(7):844-850. doi: 10.1177/1076029616673732. Epub 2016 Oct 17.

PMID:
28301899
46.

Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Miura K, Nakagawa M, Takahashi H, Uchino Y, Kodaira H, Iriyama N, Sakagami M, Ohtake S, Kobayashi S, Hojo A, Kurita D, Kobayashi Y, Kusuda M, Hirabayashi Y, Hatta Y, Takei M.

Int J Hematol. 2016 Mar;103(3):334-40. doi: 10.1007/s12185-015-1926-6. Epub 2015 Dec 29.

PMID:
26715149
47.

Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.

Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, Miyawaki S, Uchida N, Maeda T, Nagamura-Inoue T, Asou N, Morishima Y, Atsuta Y, Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y.

Eur J Haematol. 2016 Sep;97(3):278-87. doi: 10.1111/ejh.12723. Epub 2016 Jan 20.

PMID:
26680003
48.

[A Case of Abdominal Wall Desmoid Tumor after Radical Nephrectomy for Renal Cancer].

Ohtake S, Namura K, Fujikawa A, Sawada T, Ohta J, Moriyama M, Hayashi H.

Hinyokika Kiyo. 2015 Sep;61(9):353-7. Japanese.

49.

Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.

Miura K, Takahashi H, Nakagawa M, Izu A, Sugitani M, Kurita D, Sakagami M, Ohtake S, Uchino Y, Hojo A, Kodaira H, Yagi M, Kobayashi Y, Iriyama N, Kobayashi S, Kiso S, Hirabayashi Y, Hatta Y, Takei M.

Leuk Lymphoma. 2016;57(6):1335-41. doi: 10.3109/10428194.2015.1096352. Epub 2015 Oct 22.

PMID:
26390147
50.

Erratum to: A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.

Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, Kashiwase K, Morishima Y, Fukuda T, Kodera Y, Doki N, Miyamura K, Mori T, Nakao S, Ohtake S, Morishita E.

Int J Hematol. 2015 Oct;102(4):507-8. doi: 10.1007/s12185-015-1867-0. No abstract available.

PMID:
26351240

Supplemental Content

Loading ...
Support Center